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Design and Evaluation of a Novel Composite Chitosan-Poly(Lactide-co-Glycolide) 
Microsphere Based System for Bone Tissue Engineering Applications.  Major Professor: 
Joel D. Bumgardner, Ph.D. 
Nearly 60% to 67% of all injuries that occur annually within the US are due to 
musculoskeletal injuries, with over a million people requiring implants and bone grafting 
materials to reconstruct bone defects.  Our lab has previously developed composite 
chitosan/nano-hydroxyapatite microsphere based bone grafts that had good compressive 
strengths, supported bone cell growth and mineralization in vitro, demonstrated 
biocompatibility and osteoconductivity in a rat calvarial defect model, and when loaded 
with rhBMP-2 was osteoinductive in a rat muscle pouch model.  However, degradation of 
these scaffolds was very slow which may have limited the amount of new bone formed in 
vivo.  The objectives of this research was to develop a novel composite Chitosan-PLGA 
microsphere based system prepared via a precipitation method with improved 
degradation and biological characteristics as compared to plain chitosan (CTS) 
microspheres.  The effect of varying PLGA amounts within the CTS microspheres was 
evaluated via degradation and biocompatibility studies in addition to physiochemical 
properties.  PLGA particles in the composite CTS-PLGA microspheres segregated to the 
surface of the microspheres resulting in roughened surface textures.  In addition, 
composite microspheres also had reduced crystallinity resulting in reduced exothermic 
peak temperatures as seen from XRD and DSC studies; showed increased degradation 
and better osteoblast attachment as compared to plain CTS microspheres. However, no 
effect was seen on osteoblast proliferation over a 7 day cell culture period.  The results of 
this study showed that composite CTS-PLGA microsphere based systems have the 
potential to be used in bone tissue engineering applications and future studies will be 




The main body of this thesis is a journal article entitled, ―Design and Evaluation 
of a Novel Composite Chitosan-Poly(Lactide-co-Glycolide) Microsphere Based System 
for Bone Tissue Engineering: Preliminary Degradation and Biocompatibility Studies.‖  
This manuscript will be submitted to the Journal of Biomedical Materials Research Part 
B: Applied Biomaterials. 
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CHAPTER 1: INTRODUCTION 
1.1 Statement of Clinical Problem 
Nearly 60% to 67% of all injuries that occur annually within the United States are 
due to musculoskeletal injuries, with upper and lower extremity fracture cases averaging 
around 12.5 million every year between 1998 and 2004.
1
  Of these, over a million people 
require implants and bone grafting materials to reconstruct bone defects from disease or 
trauma each year,
2
 costing between $34,000 to $37,000 per procedure.
3
  Autografts 
remain the ―gold standard‖ for stimulating bone growth and regeneration owing to its 
osteoconductive, osteoinductive and osteogenic properties.
4-6
  Allografts, on the other 
hand, possess the same properties as autografts but with lesser osteoinductive and 
osteogenic properties.
7,8
  These bone graft substitutes, however, are limited in their use 
due to their availability and complications such as tissue morbidity, immunological 
rejection and disease transmission that are associated with them.
4,6,8-10
  As a result of the 
limitations surrounding the use of autografts and allografts as bone graft substitutes, there 
is a pressing clinical need for the development of biologically active bone graft 
substitutes that can be used to treat non-union musculoskeletal injuries.
6-8
  





  and microsphere 
15-17
 for various tissue engineering and drug delivery 
applications. In particular, our chitosan-based microsphere constructs for use as a bone 
graft substitute material for bone tissue engineering and local drug delivery have been 
prepared by a novel precipitation method.
15-17
  These microspheres are then fabricated 
into three-dimensional constructs to mimic the porous architecture of cancellous bone.  
Research has shown that these constructs have proven to have good compatibility with 
2 
 
osteoblasts and have demonstrated to have mechanical properties and porosity sufficient 
to support new bone growth in vitro as well as in vivo.
15,16
  Furthermore, these 
microspheres can be loaded with desired proteins and growth factors such as BMP-2 to 
enhance their osteoconductivity and promote bone growth.
17
  However, in vitro and in 
vivo studies have shown that chitosan-based microsphere bone graft constructs exhibit a 
slow degradation profile.
15-17
  A slow degradation profile could potentially limit the 
continuous production and/or retard growth of bone within the chitosan scaffold and the 
defect area;
18
 therefore limiting the use of chitosan as a bone graft for bone tissue 
engineering applications.  Hence, an improvement in the degradation profile of the 
chitosan microsphere-based bone graft material is needed to further optimize and 
improve the desirable properties and characteristics of the scaffold design for bone tissue 
engineering and local drug delivery applications. 
1.2 Hypothesis and Objectives 
According to Roberts, it takes around 18 weeks in humans for the reparative 
phase of bone healing and up to 54 weeks for the remodeling phase
19
 and maturation of 
bone.
20
  Based on this, ideally, we would prefer a bone scaffold that degrades without 
losing its mechanical strength within the first 4-6 months which would provide the much 
needed initial support, followed by complete degradation within the year which would 
allow space for native bone to regenerate and grow.  In this work, our strategy is to 
develop a composite system with chitosan and poly(lactide-co-glycolide) so that we can 
tailor the degradation profile of chitosan to match our desired goal, while maintaining its 
osteoconductive and osteoinductive properties. 
3 
 
We hypothesize that the incorporation of 50:50 poly(lactide-co-glycolide) or 
PLGA into chitosan microspheres by a precipitation method increases the 
degradation rate of the chitosan microspheres. Furthermore, we hypothesize that 
incorporating 50:50 PLGA into chitosan microspheres will have no effect on 
compatibility of microspheres with osteoblasts. 
The rationale behind this hypothesis is that chitosan is known to have immense 
potential as an orthopaedic biomaterial
21-27
 but chitosan based 3D scaffolds have very low 
degradation rates which could limits its use in tissue engineering and drug delivery 
applications.  Furthermore, chitosan is known to degrade in acidic conditions
28,29
 and 
50:50  PLGA is known to degrade rapidly, releasing acidic by-products 
30-32
 which could 
potentially drive the degradation of chitosan.  
1.2.1 Objectives 
To test these hypotheses, the following specific objectives were undertaken: 
Objective I  
Prepare and characterize composite Chitosan-PLGA microspheres.  
a) Prepare PLGA particles via an emulsion-diffusion-evaporation technique. 
b) Incorporate PLGA particles into chitosan microspheres (25 wt% and 50 wt%) 
via a precipitation method. 
c) Determine the amount of PLGA within the composite Chitosan-PLGA 
microspheres. 
d) Characterize the composite Chitosan-PLGA microspheres for amount of 
PLGA using confocal imaging; for shape and surface morphology using 
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digital microscopy; for crystallinity via x-ray diffraction spectrometry; and 
thermal degradation properties via differential scanning calorimetry. 
Objective II  
Characterize the degradation profile of composite Chitosan-PLGA microspheres 
over a two month period in a lysozyme solution.    
a) Determine the change in mass of the composite microspheres over the two 
month period as compared to plain chitosan microspheres.  
b) Evaluate the change in surface topography in the composite microspheres 
using digital microscopy. 
Objective III  
Evaluate the ability of human osteosarcoma bone cells (Saos-2) to attach and 
proliferate on the composite Chitosan-PLGA microspheres over a week. 
a) Determine the percent cell attachment on the surface of the composite 
microspheres as compared to plain chitosan microspheres. 
b) Determine the proliferation of cells on the surface of the composite 
microspheres quantitatively as well as qualitatively as compared to plain 
chitosan microspheres. 
1.2.2 Significance 
We propose preparing composite Chitosan-PLGA microspheres using a unique 
method of incorporating PLGA particles within chitosan microspheres via a precipitation 
method.  The incorporation of PLGA would help increase the degradation rate of chitosan 
scaffolds without losing mechanical strength.  As the PLGA particles degrade, the acidic 
5 
 
by-products produced will help drive the degradation of chitosan, providing a means for 
increasing and subsequently optimizing the overall degradation rate of the composite 
Chitosan-PLGA microspheres.  This research is significant as the results would provide 
data on the potential of using a composite Chitosan-PLGA microsphere system as a bone 
graft material for bone tissue engineering applications for the treatment of bone fractures 
and defects.  
6 
 
CHAPTER 2: LITERATURE REVIEW 
2.1 Bone injury and repair 
It has been reported that nearly six million bone fractures occur every year in the 
United States alone.
19
  A fracture is usually caused by the inability of bone to withstand 
an applied external force. When bone is injured or fractured, it has the inherent 
physiological property and response mechanisms to heal, repair and model itself back to 
its pre-injured condition. The complexity and pattern of the fracture decides the healing 
process associated with it.  
Usually, bone healing follows three important and distinct phases: the early 
inflammatory phase, the reparative phase, and the late remodeling phase.
33-36
  The first 
phase of the bone healing process begins with the formation of a blood clot or hematoma 
at the fracture site which works to stabilize the fracture.  The cocktail of inflammatory 
cytokines and chemokines produced in response to the fracture results in the recruitment 
and migration of macrophages, fibroblasts, osteoblasts, mesenchymal stem cells (MSCs) 
and vascular stem cells to the fracture site which initiates the bone healing process. This 
is then followed by the reparative phase of bone healing during which a soft callous of 
cartilage is produced around the fracture site by chondrocytes which is then mineralized 
by osteoblasts creating a hard callous of woven bone.  At this point during the healing 
process, the bone structure is disorganized and as a result very weak and prone to re-
fracture.  Remodeling of this weak woven bone into more organized lamellar bone is 
necessary and occurs during the final remodeling phase of the bone healing process.  
Osteoclasts and osteoblasts work together at this stage to remodel woven bone into 
lamellar bone and restore the bone to its pre-injured state, shape and strength.
33,37-42
  It 
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takes around 18 weeks in humans for the reparative phase of bone healing to take place, 
which includes the formation of a woven callus and lamellar compaction.  This is 
followed by ―interface remodeling and compacta maturation of the bone‖ which occurs at 
54 weeks 
53
.   
The above described healing process works well for simple fractures.  However, 
for more complex fractures and defects that disrupt bone-to-bone interaction, normal 
physiological bone healing is inhibited resulting in delayed or non-union bone 
fractures
43
—these fractures generally lead to scarring rather than regeneration.
44
  These 
fractures are a result of complex musculoskeletal trauma, failing to heal even after several 
months of occurrence.
45
  They are associated with a number of risk factors such as soft-
tissue injury, physiological compromise, extensive bone loss, fracture instability and 
infection.
46
   
There is not much research done on what the critical size bone defect is in 
humans, but usually a defect > 1cm is often considered to be a critical size defect.
47
  A 
number of animal studies in larger animals such as sheep use long bone critical size 






  Usually, non-union treatments with critical 
size bone defects involve surgical intervention such as bone graft implantation in 
conjunction with internal fixation is required in addition to long-lasting therapies to 
restore bone continuity and stability.
7,51
   
2.2 Bone grafts 
Bone grafts are used to repair complex bone fractures in cases of complex 
musculoskeletal trauma that pose potential health risks to the patient and fail to heal after 
several months.  According to Glassman and coworkers, bone graft procedures range 
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from approximately $33,860 to $37,227 and includes but is not limited to the actual cost 
of the bone graft, surgeon and anesthesiologist fees, hospital charges, medication charges 
as well as additional fees for services such as medical supplies, diagnostic procedures and 
equipment use fees.
3
  In the United States alone, over 500,000 bone grafting procedures 
have been performed and it is estimated that with the increase in age-related fractures the 
number of procedures performed by the year 2020 will reach 51.5 million.
52,53
   
 Bone grafts help to bridge the gap between bones at the fracture site and serve as 
a temporary support with some mechanical integrity and a favorable environment for 
osteogenesis, osteoconduction, and possible osteoinduction—important properties 
required for bone healing and remodeling.  Bone grafts are usually implanted in 
conjunction with either an internal or external fixation device to provide for additional 
mechanical support while the bone heals and remodels, restoring bone continuity at the 
fracture site.   
The most common types of bone grafts currently used are autografts and 
allografts.  Despite their many advantages with regard to their osteoconductivity, 
osteoinductivity and possible osteogenicity, these bone grafts are known to have their 
disadvantages too which have caused researchers to explore other alternatives, such as 
synthetic bone grafts.  
2.2.1 Autografts 
Autografts remain the ―gold standard‖ for stimulating bone growth and 
regeneration owing to its osteoconductive, osteoinductive and osteogenic properties.
4-6
  
Autografts are commonly defined as tissues grafted from one part of an individual to 
another part of the same individual.  Bone autografts are generally extracted from the 
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iliac crest, the fibula, the mandible and even parts of the skull of the patient.  The surgical 
procedure involving the harvesting of autologous bone graft, however, is associated with 
a number of complications for the patient including tissue morbidity, nerve and muscle 
damage, chronic pain as well as infection.
6,54-58
  Furthermore, there is limited availability 




Allografts offer an alternative approach for the treatment of non-union bone 
fractures with the same characteristics as autografts but they lack osteogenic properties 
due to the absence of viable osteogenic cells.
6,8
  Allografts are defined as tissues grafted 
from one individual to another individual and are usually obtained from cadavers.  Bone 
allografts are often used either as fresh or fresh-frozen bone, freeze-dried bone allografts, 
or demineralized freeze-dried bone allografts.  Some advantages of allografts over 
autografts are its availability in different shapes and sizes and no donor site tissue 
morbidity.
6
  However, there are complications associated with allografts and include 
disease transmission and immunogenicity.
6,8,10 
2.2.3 Synthetic bone grafts 
Currently, much research is directed towards the development of synthetic bone 
graft substitutes in order to obviate the limitation regarding autografts and allografts for 
the treatment of non-union bone fractures.  Bone tissue engineering approaches focus on 
the use of synthetic scaffolds that mimic the physical and mechanical nature of bone 
while inducing bone healing through the use of growth factors, preventing infection with 
the use of antibiotics and providing an environmentally favorable matrix for cells to grow 
10 
 
and proliferate for new bone formation.
5
  For this purpose, ideally, synthetic bone grafts 
should be biocompatible, porous in structure to allow for cellular infiltration and 
vascularization, osteoconductive, osteoinductive, biodegradable, have similar mechanical 
properties as bone, undergo remodeling and support generation of new bone.
5,8,59,60
.   
From an engineering perspective, synthetic bone graft scaffolds for bone tissue 
engineering should meet the following requirements: 1) Three-dimensional 
architecture—possess interconnecting pores of appropriate size to promote tissue 
integration and vascularization, 2) Biocompatibility—not elicit an immune response that 
would cause the host to reject the bone graft, 3) Osteoconductivity—provide a matrix 
upon which osteoblasts can proliferate and generate new bone, 4) Osteoinductivity—
stimulate osteoprogenitor cells to differentiate into bone forming cells or osteoblasts, 5) 
Biodegradable—possess a controlled degradation rate so that native tissue will gradually 
replace the bone graft, 6) Biomechanics—have adequate mechanical properties to match 
cancellous bone or the intended site of implantation, and 7) be easy to manufacture, 
sterilize and handle in the operating room.
19,26
  
2.3 Biomaterials used in bone tissue engineering applications 
All criteria for an ideal synthetic bone graft for bone tissue engineering 
applications cannot be achieved without the use of a biomaterial.  Hence, large emphasis 
is put on choosing the right biomaterials for use as a synthetic bone graft as biomaterials 
are an essential part of tissue engineering strategies.  However, fabricating a bone 
scaffold with all the essential requirements poses a significant challenge for researchers 
and therefore a lot of research is being done to better understand biomaterials so that 
ideal bone graft scaffolds can be fabricated and engineered.  
11 
 
The most common type of biomaterials used as bone grafts for bone tissue 
engineering applications are ceramics, polymers, or a composite of ceramics and 
polymers.  Both ceramics and polymers can be either resorbable or non-resorbable, and 
polymers can be either naturally derived or derived from synthetic sources.
61
 These 
biomaterials can be constructed into three-dimensional structures that are 
osteoconductive, osteoinductive and with sufficient mechanical integrity, making them 
suitable as bone graft scaffolds for bone healing and remodeling.  Each of these 
biomaterials comes with their set of pros and cons, and biomaterial researchers have been 
trying to manipulate these materials so that their advantages can be maximized and their 
disadvantages minimized.    
2.3.1 Ceramics 
Ceramics are inorganic and nonmetallic substances known for their high 
compressive strengths. They have been used over the years in a variety of dental and 
orthopaedic applications because of their similarity to the mineral phase of bone—
making them osteoconductive—and due to their ability to form direct bonds with the 
surrounding bone.
61
 The most commonly studied ceramics for use as bone graft scaffolds 
include calcium carbonates, calcium sulfates, calcium phosphates and bioactive glass.  
Ceramics are desired because they are biocompatible and elicit minimal immunological 
and foreign body reactions due to the lack of proteins associated with them.
61
  Most 
ceramics, however, are not osteoinductive.
61
  Furthermore, ceramics have a high 
resistance to deformation causing it to be brittle and they are also difficult to machine 






Polymers used as bone graft substitutes for bone tissue engineering applications 
can be either derived from natural sources—polysaccharides such as alginate, chitin, 
chitosan and hyaluronic acid, or proteins such as collagen, fibrin and silk—or from 
synthetic sources such as poly(lactic acid), poly(glycolic acid), poly(lactide-co-
glycolide), poly(ε-caprolactone) and poly(hydroxyl butyrate).  Naturally derived 
polymers are known to support cell attachment but have poor mechanical strength and are 
limited in supply, making them costly.
63
  On the other hand, synthetic polymers have 
relatively good mechanical strength, tunable degradation rates and can be manipulated 
into desired shapes, but lack moieties that support cell adhesion.
63
  However, it should be 
noted that some synthetic polymers have undesirable acidic degradation products and low 
cellular compatibility, whereas natural polymers have limited degradation and lower 




Composite systems are often prepared to utilize the advantageous properties of 
two or more materials involved while reducing their disadvantages.  For example, 
polymer composites with ceramics have been formulated and investigated as bone tissue 
engineering constructs to increase the mechanical strength of the polymer while retaining 
the osteoconductive and biodegradative properties of the polymer.   
Chesnutt et al. prepared a novel chitosan/nano-hydroxyapatite composite bone 
scaffold using a co-precipitation method.
15
  The results of their study showed that the 
addition of hydroxyapatite to chitosan resulted in an increase in surface roughness and 
area of the scaffolds, increase in compressive modulus of the scaffolds (nearly 300% 
13 
 
increase), and had increased osteoblast proliferation as compared to chitosan scaffolds, 
hence making it a better bone graft material.
15
  
Wu et al. used a similar strategy, wherein they used composite PLGA scaffolds to 
make them better suited as tissue regeneration scaffolds.
65
  They prepared PLGA 
scaffolds and coated them with collagen, chitosan or N-succinyl-chitosan.  The results of 
their study showed that PLGA scaffolds coated with collagen had increased cellular 
attachment and proliferation as compared to PLGA scaffolds alone.
65
  Furthermore, their 
study showed that PLGA scaffolds coated with chitosan had reduced degradation rates 
and resulted in greater differentiation of osteoblastic stromal cells based on alkaline 
phosphatase activity as compared to PLGA scaffolds alone.
65
  By coating a synthetic 
polymer with naturally derived materials, Wu and coworkers were able to modify the 
microenvironments of PLGA scaffolds making them osteoconductive and osteoinductive, 
and hence suitable for tissue engineering applications.    
2.4 Chitosan 
Chitosan, a partially N-deacetylated derivative of chitin, a natural polysaccharide 
derived from the exoskeleton of crustaceans.  It has shown to have immense potential as 
an orthopaedic biomaterial with many attractive properties—osteoconductivity, 
biocompatibility, non-toxic and non-acidic degradative products, formable into three-




Chitosan can easily be formed into microspheres to make bone scaffolds with 
good mechanical strength and porosity to support bone cell in-growth 
15,16
  and as an 
efficient drug and protein delivery vehicle.
17,66
  Despite its many appealing properties for 
14 
 
bone growth and regeneration and its use as a therapeutic agent delivery protein delivery 
vehicle, biodegradation rate of chitosan microsphere-based scaffolds has been very low. 
A slow degradation profile could potentially limit the continuous production or even 
retard growth of bone within the chitosan scaffold and the defect area;
18
 therefore 
limiting the use of chitosan as a bone graft for bone tissue engineering and drug delivery 
applications.  
Degree of deacetylation and molecular weight are two important properties of 
chitosan and are known to affect its physicochemical and biological properties.  It has 
been reported that biodegradation of chitosan increases with decrease in degree of 
deacetylation of chitosan 
67,68
 as well as with decrease in molecular weight of the 
polymer.
69,70
  Thus, choosing chitosan with a lower degree of deacetylation and 
molecular weight could be one possible route for increasing the polymer’s degradation 
rate.  
Conversely, it has also been reported that mechanical strength of chitosan 
decreases with the decrease in the degree of deacetylation
71,72
 and molecular weight of 
chitosan.
73
  It is imperative that chitosan scaffolds for bone tissue engineering 
applications would need to possess mechanical strength while being able to degrade.  
Hence, lowering the degree of deacetylation and molecular weight to increase 
biodegradation of the polymer is not the best choice and alternate routes need to be 
explored.  
2.5 Poly(lactide-co-glycolide) 
One alternative is to use chitosan in conjunction with the co-polymer poly(lactide-
co-glycolide) or PLGA which is part of the family of poly(α-esters).  Other members of 
15 
 
the family of poly(α-esters) include poly(glycolic acid) (PGA) and poly(lactic acid) 
(PLA).  PGA is a highly crystalline polymer and exhibits a high tensile modulus and high 
rate of degradation.
74
  PLA, on the other hand, is also crystalline and is a slow degrading 
polymer compared to PGA and has good tensile strength and a high modulus.
74
  
PLGA, a synthetic co-polymer of lactic acid and glycolic acid, forms amorphous 
polymers.
74
  It is known for its biocompatibility, biodegradability and mechanical 
strength.
30-32,75
  PLGA is known to degrade via hydrolysis releasing the original 
monomers—both of which are acidic.
30-32
  The 50:50 PLGA is very unstable and 
degrades in approximately 1-2 months.
74
  Furthermore, PLGA nanoparticles have been 











 and hormones 
80
 to name a few.  
2.6 Composite Chitosan-PLGA materials 
A number of research labs in the recent years have formulated composite 
chitosan-PLGA systems for bone tissue engineering applications in a variety of forms 






  The inspiration behind 
formulating composite systems for bone tissue engineering applications such as one with 
chitosan and PLGA is to take advantage of the biocompatibility and osteoconductive 
properties of chitosan and mesh it with the mechanical strength, tailorable degradation 
and drug delivery properties of PLGA, creating a superior bone graft scaffold material 
that is better than chitosan or PLGA alone.  
For example, Yilgor and coworkers have reported making PLGA nanocapsules 
loaded with BMP-2 or BSA which were then loaded either within or onto chitosan 3D 
mesh fiber scaffolds.
81
  The PLGA nanospheres were loaded with bone morphogenetic 
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protein-2 (BMP-2) or bovine serum albumin (BSA) by a double emulsion-solvent 
evaporation technique.  The chitosan 3D mesh fibers were prepared by a wet-spinning 
method.  In order to incorporate the PLGA nanocapsules within the chitosan fiber mesh, 
the nanocapsules were mixed with the chitosan solution before the wet-spinning 
process.
81
  On the other hand, to incorporate the PLGA nanocapsules on the chitosan 
fiber mesh, 100μL of nanocapsules solution was applied to either side of the wet-spun 
chitosan fiber mesh, applied through a series of vacuum-pressure cycles, and dried 
overnight in a vacuum.
81
  Yilgor et al. reported that the chitosan fiber meshes with PLGA 
nanocapsules containing BMP-2 were better at differentiating bone marrow MSCs, based 
on the increased alkaline phosphatase (ALP) activity of the cells, as compared to PLGA 
nanocapsules alone.
81
  Furthermore, they claimed that drug delivery was better in the 
system where the nanocapsules were attached onto the chitosan fiber mesh as compared 
to the system where the nanocapsules were within the chitosan fiber mesh.
81
  They 
suggest that sequential growth factor delivery via these nanocapsules on chitosan fiber 
meshes would be a better approach in bone tissue engineering applications than 
individual growth factor delivery as it would mimic the natural process of bone healing.
81
 
Recently, Nandagiri et al. prepared porous chitosan-gelatin scaffolds (chitosan-
gelatin in a 1:2 ratio by weight) embedded with various amounts of BSA loaded PLGA 
nanoparticles.
82
  BSA loaded PLGA nanoparticles were also prepared by a double 
emulsion-solvent diffusion method.  The chitosan-gelatin scaffolds crosslinked with 
genipin were prepared by lyophilization.  PLGA nanoparticles were embedded within 
these chitosan-gelatin scaffolds by dispersing an aqueous suspension of PLGA 
nanoparticles into the chitosan-gelatin solution at different weight concentrations (16.6%, 
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33.3% and 66.6% respect to chitosan-gelatin weight), followed by crosslinking with 
genipin and then undergoing a lyophilization process to prepare sponge scaffolds.
82
  
Nandagiri et al. reported that the addition of PLGA nanoparticles to the chitosan-gelatin 
scaffolds modulated physical and mechanical properties of the chitosan-gelatin 
scaffolds.
82
  In particular, increasing PLGA wt% within the chitosan-gelatin scaffolds 
resulted in a decrease in water uptake, increase in compressive modulus and an increase 
in dissolution over a ten day period.
82
  However, there was no effect of PLGA wt% 
concentration on the attachment and proliferation of clonal human osteoblast cell line 
(hFOB) over an eleven day period on the chitosan-gelatin scaffolds.
82
  Interestingly, the 
authors claimed that the delivery of BSA from the PLGA nanoparticles was prevented 
―by properly selecting the pH of the external aqueous phase‖ and ―by increasing its 
osmolality by adding sodium chloride‖—no BSA delivery data was reported.  They 
concluded that the 33wt% PLGA within chitosan-gelatin scaffold formulation had the 
best mechanical properties (~50KPa) and retained desirable physical and cell attachment 
properties as compared to the other formulations, and future studies will study the 
encapsulation and release of therapeutic proteins such as BMP-2 and parathyroid 
hormone (PTH) from this optimized formulation.
82
  
Jiang et al. have reported making chitosan/PLGA sintered microsphere scaffolds 
using the solvent-evaporation technique.
83,84
  Briefly, chitosan particles were mixed with 
20% w/v PLGA solution in methylene chloride.  The mixture was vortexed and 
subsequently poured into 1% polyvinyl alcohol solution under constant stirring to allow 
the methylene chloride to evaporate.  The resultant particles were washed with DI water, 
filtered, lyophilized, sieved to different sizes and stored in a dessicator for further use.  
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They claimed that their chitosan/PLGA sintered microspheres had compressive modulus 
and compressive strain within the range of human trabecular bone making them suitable 
as scaffolds for load-bearing bone tissue engineering applications.
83
  They also reported 
that the composite chitosan/PLGA sintered microsphere scaffolds had better 
biocompatibility to MC3T3-E1 osteoblast-like cells as compared to PLGA scaffolds 
alone.
83
  Furthermore, they suggest that the presence of chitosan in the composite 
scaffolds resulted in an increase in alkaline phosphotase activity of the cells cultured on 
the composite microspheres as well as up-regulated the gene expression of alkaline 
phosphatase, ostepontin and bone sialoprotein.
83
  In a follow up paper, they reported that 
over a 12 week degradation period, the compressive strain and compressive modulus of 
the composite scaffolds remained in the range of human trabecular bone.
84
   
2.7 Summary 
 These studies outline the benefits of using composite chitosan-PLGA materials.  
As summarized, these composite materials exhibited biocompatibility and 
osteoconductivity with osteoblast-like cells due to increased alkaline phosphatase activity 
of the cells, and had compressive strains and compressive modulus in the range of human 
trabecular bone.  In these studies, essentially, the biocompatibility and osteoconductive 
properties of chitosan were meshed with the mechanical strength, tailorable degradation 
and drug delivery properties of PLGA.  We hope to adopt a similar strategy by preparing 
composite CTS-PLGA microspheres using a unique method of incorporating 50:50 
PLGA particles within chitosan microspheres via a precipitation method.  The 
incorporation of PLGA particles would help increase the degradation rate of chitosan 
scaffolds without compromising the overall mechanical strength.  As the PLGA degrades, 
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the acidic by-products produced will be able to help drive the degradation of chitosan, 
providing a means for increasing and subsequently optimizing the overall degradation 
rate of the composite CTS-PLGA microspheres.  Thus, this research would provide data 
on the potential of using a composite CTS-PLGA microsphere system prepared via a 
precipitation method as a bone graft material for bone tissue engineering applications for 




CHAPTER 3: PLANNED SUBMISSION TO JOURNAL OF BIOMEDICAL 
MATERIALS RESEARCH PART B 
DESIGN AND EVALUATION OF A NOVEL CHITOSAN-POLY(LACTIDE-CO-
GLYCOLIDE) MICROSPHERE BASED SYSTEM FOR BONE TISSUE 
ENGINEERING: PRELIMINARY DEGRADATION AND BIOCOMPATIBILITY 
STUDIES 
Abstract 
Our research group has previously researched composite chitosan/nano-
hydroxyapatite microsphere based bone grafts that had favorable mechanical and 
osteoconductive properties as a bone graft substitute.  However, degradation of these 
scaffolds was very slow which limited the amount of new bone formed in vivo.  The 
objectives of this research was to develop a novel composite Chitosan-PLGA 
microsphere based system prepared via a precipitation method with improved 
degradation and biological characteristics as compared to plain chitosan (CTS) 
microspheres.  Three different formulations of composite CTS-PLGA microspheres were 
prepared: a) CP0 (100wt% CTS, 0wt% PLGA); b) CP25 (75wt% CTS, 25wt% PLGA); 
and c) CP50 (50wt% CTS, 50wt% PLGA).  The effect of varying PLGA amounts within 
the CTS microspheres was evaluated via degradation and biocompatibility studies in 
addition to physiochemical properties.  PLGA was incorporated within the composite 
microspheres—7.5wt% for CP25 and 12.6wt% for CP50. Digital and confocal imaging 
suggested that PLGA particles in the composite CTS-PLGA microspheres segregated to 
the surface of the microspheres resulting in roughened surface textures.  XRD analysis 
showed that the addition of PLGA resulted in reduced crystallinity which was reflected in 
the reduced exothermic peak temperatures in DSC.  CP25 had the highest percent weight 
loss (28.2% ± 1.4%); while CP0 had the lowest percent weight loss (25.2% ± 0.3%) at the 
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end of the 28 day degradation period.  Highest percent osteoblast attachment was seen for 
CP25 (35.3% ± 5.5%), followed by CP50 (30.2% ± 4.3%) and CP0 (23.1% ± 7.7%); 
however, no effect was seen on osteoblast proliferation over a 7 day cell culture period.  
These results show that composite CTS-PLGA microsphere based systems have the 
potential to be used in bone tissue engineering applications and future studies will be 
aimed at evaluating its potential as a dual drug delivery vehicle. 
Keywords: chitosan, PLGA, composite chitosan microspheres, degradation, osteoblast 
cell culture  
Introduction 
Nearly 60% to 67% of all injuries that occur annually within the United States are 
related to musculoskeletal injuries, with upper and lower extremity fractures cases 
averaging around 12.5 million every year between 1998 and 2004.
1
  Of these, over a 
million people require implants and bone grafting materials to reconstruct bone defects 
from disease or trauma each year,
2
 costing between $34,000 to $37,000 per procedure.
3
  
Autografts remain the ―gold standard‖ for stimulating bone growth and regeneration 
owing to its osteoconductive, osteoinductive and osteogenic properties.
4-6
  Allografts, on 
the other hand, possess the same properties as autografts but with lesser osteoinductive 
and osteogenic properties.
7,8
  These bone graft substitutes, however, are limited in their 
use due to their availability and complications such as tissue morbidity, immunological 
rejection and disease transmission that are associated with them.
4,6,8-10
  As a result of the 
limitations surrounding the use of autografts and allografts as bone graft substitutes, there 
arises a clinical need for the development of bone graft substitute materials that can be 





A promising material for developing bone graft substitutes is chitosan. Chitosan 
(CTS) is a partially N-deacetylated derivative of chitin, a natural polysaccharide derived 
principally from exoskeleton of crustaceans. CTS exhibits many attractive properties—
osteoconductivity, biocompatibility, non-toxic and non-acidic degradative products, 
formable into three-dimensional (3D) scaffolds—making it a good candidate for bone 
graft substitute applications.
21-27
  For example, Bhat et al. reported that mesenchymal 
stem cells (MSCs) (obtained from the femora and tibiae of Dark Agouti rats) seeded onto 
tripolyphosphate cross-linked chitosan microparticles resulted in a significant increase in 
bone formation after 8 weeks of implantation in a partial thickness rat femur bone defect 
as compared to a stainless steel plate control.
85
  Stephan et al. showed that an injectable 
form of tissue engineered bone using a chitosan gel, MSCs and BMP-2 enhanced bone 
formation in a rat calvarial critical sized defect.
47
  These studies with chitosan based bone 
grafts are promising; however, the need for strength of bone graft substitutes has not been 
met.  
To take advantage of the many desirable characteristics of CTS and to enhance 
mechanical properties, our research group developed a composite chitosan/nano-
hydroxyapatite microsphere-based scaffold.
15,16
  The microsphere-based scaffolds had 
compressive strengths on par with lower range of cancellous bone (~10 MPa), supported 
bone cell growth and mineralization in vitro, demonstrated biocompatibility and 
osteoconductivity in a rat calvarial defect model, and when loaded with BMP-2 was 
osteoinductive in a rat muscle pouch model.
15,16,86
  However, only 2% weight loss of 





  Improvements in the degradation profile of the CTS microsphere-based 
scaffolds may result in improved bone regeneration.  
Our research strategy was to use CTS in conjunction with the co-polymer 
poly(lactide-co-glycolide) or PLGA.  PLGA is a biocompatible polymer that degrades via 
hydrolysis, releasing acidic degradation products.
30-32
  Since CTS is soluble at acidic pH, 
the degradation of the PLGA particles may help to increase the degradation of the CTS 
microspheres.  The aim of this study was to develop a novel composite CTS-PLGA 
microsphere based system and evaluate the effect of different weight percent of PLGA 
within CTS microspheres (0 wt %, 25 wt % and 50 wt %) on degradation rate and 
compatibility with cultured cells. In this study, a 50:50 PLGA is used since this 
formulation is hydrolytically unstable and is reported to completely degrade within 
approximately 1-2 months.
74
  Composite CTS-PLGA and plain CTS microspheres were 
prepared by a precipitation method.  Our primary hypothesis is that the incorporation of 
50:50 PLGA into CTS microspheres increases the overall degradation of the CTS 
microspheres.  Our secondary hypothesis is that incorporating 50:50 PLGA into 
microspheres will have no cytotoxic effect on compatibility of composite microspheres 
with osteoblasts.   
Materials and Methods 
Preparation and Characterization of PLGA Particles 
50:50 PLGA (D,L-Lactide—46 mole%; Glycolide—54 mole%; Molecular 
weight—3.2 KDa; Inherent viscosity—0.08dL/g; Lakeshore Biomaterials, Alabama, 
USA) particles were prepared by modifying an emulsion-diffusion-evaporation technique 
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described by Betram et al. and Ravikumar et al.  Briefly, a 2% weight/volume (w/v) 
solution of 50:50 PLGA in acetone (50mL) was dripped drop wise into a 1% w/v solution 
of polyvinyl alcohol (PVA) under magnetic stirring at 1200 rpm.  The solution was 
ultrasonicated at 35% amplitude using the following sequence: 20 seconds ON, 20 
seconds OFF, 20 seconds ON, 20 seconds OFF, 20 seconds ON, and then added to a 5% 
w/v solution of PVA and stirred at 350 rpm overnight in a fume hood.  The emulsion was 
then centrifuged at 13,500xg for 20 minutes, washed with DI water three times, re-
suspended in DI water and freeze dried for 24 hours to obtain PLGA particles.  The 
PLGA particles were stored in centrifuge tubes at -4
0
C until further use.  The prepared 
PLGA particles were characterized for their crystallinity using x-ray diffraction (XRD) 
spectrometry and thermal degradation properties using differential scanning calorimetry 
(DSC).  
Preparation of Composite Chitosan-PLGA Microspheres 
Composite microspheres were prepared from a CTS (CTS) solution containing 
PLGA.  A 4.375 wt% solution of CTS powder (Degree of deacetylation—61%, 
Viscosity—124cP, Primex, Iceland) was prepared in 2.5 v/v% acetic acid solution and 
allowed to dissolve for 48 hours and then filtered using a nylon mesh with a pore 
diameter of 180μm (Gilson Company, Inc., Ohio, USA).  PLGA particles suspended in 
water were added to the filtered CTS solution in the following weight ratios of 
CTS:PLGA, a) 100:0 (CP0), b) 75:25 (CP25), and c) 50:50 (CP50) (Table 1).  To form 
microspheres, the PLGA-CTS solutions were dripped using a 16G needle and a syringe 
pump set at a flow rate of 10μL/min into a cold base solution (50 wt% DI water, 30 wt% 
methanol, and 20 wt% sodium hydroxide) to precipitate microspheres.  The microspheres 
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were allowed to sit in the base solution for 5 mins before being collected.  Each batch of 
collected microspheres was then washed thoroughly with DI water to neutral pH and 
tested using a pH paper.  The CTS-PLGA microspheres were air dried in a fume hood 
overnight. 
Amount of PLGA within Composite Chitosan-PLGA Microspheres 
The amount of PLGA within each CTS-PLGA formulation was estimated by first 
dissolving a given weight of each composite microsphere formulation in 2% v/v HAc 
(aqueous phase) at a concentration of 10mg/mL for 2 hours.  To this an equal volume of 
dichloromethane (organic phase) was added, the solutions vortexed, and then allowed to 
sit for 30 mins for the two layers to separate.  The aqueous and organic phases were 
collected separately and the samples were dried in a 50
0
C oven for 24 hours.  The amount 
of CTS and PLGA within each composite microsphere was determined using the 
equations below: 
       
  
 
     
      
  
 
     
where, W is the weight of the composite CTS-PLGA microspheres, and W0 and WA are 
the weight of the dried organic and aqueous phases of the composite CTS-PLGA 
microspheres respectively.  
Physicochemical Characterization Composite CTS-PLGA Microspheres 
The physicochemical characterization of composite CTS-PLGA microspheres 
was evaluated using confocal imaging to determine whether PLGA was incorporated in 
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the composite microspheres; digital microscopy for surface topographical analysis; XRD 
spectrometry to evaluate changes in crystallinity; and DSC to evaluate thermal 
degradation properties. 
For confocal imaging analysis, a fluorescent dye, Rhodamine-B (courtesy of Dr. 
T. Fujiwara), was encapsulated within the PLGA particles using a double emulsion-
diffusion-evaporation technique, prior to incorporating the PLGA particles within the 
CTS microspheres.  Samples were placed in a glass bottom Petri dish and observed with 
the 10x objective of a Nikon A1 confocal laser fluorescence inverted microscope using 
the 488 nm and 561 nm laser lines and the NIS-element imaging software.  Surface 
topographical analysis of the composite CTS-PLGA microspheres was performed using a 
KEYENCE VHX 1000 digital microscope.  Samples were placed on a glass slide and 
viewed with a 100x objective eyepiece.  In both cases, images of the composite CTS-
PLGA microspheres (CP25 and CP50) were compared to images of plain CTS 
microspheres (CP0). 
XRD analysis on the composite CTS-PLGA microspheres was performed on a 
Bruker D8 Advance (Bruker AXS Inc., Madison, WI) using Cu-Kα radiation at 40 kV and 
40mA.  The diffraction patterns were obtained in the 2θ scan range of 4-40
0
 with a step 
size of 0.05
0
 and a time/step of 0.2 s.  DSC analysis of composite CTS-PLGA 
microspheres was performed on a NETZSCH DSC 200 PC (NETZSCH DSC 






C/min.  The 
XRD and DSC scans (n=3) for each of composite CTS-PLGA microspheres (CP25 and 




In Vitro Degradation of Composite CTS-PLGA Microspheres 
The in vitro degradation of composite CTS-PLGA microspheres was evaluated 
over a 4 week period: Days 1, 3, 5, 7, 14, 21 and 28.  A degradation solution of 
100μg/mL concentration of lysozyme in 1x PBS with 1x AB/AM (Penicillin-10,000 
IU/mL, Streptomycin-10mg/mL, Amphotericin B-25µg/mL) was used.  Each treatment 
group was gamma sterilized prior to starting the study.   
Samples (n=4) for each of the composite CTS-PLGA treatment group was 
weighed and placed in glass scintillation vials.  To each sample, 2mL of degradation 
solution was added and the samples were placed in an incubator at 37
0
C with constant 
shaking using a plate rocker.  Every 72 hours, for 4 weeks, degradation solutions were 
replenished.  At each time point, the samples were washed with DI water three times 
before drying in an oven at 40
0
C for 24 hours, weighed and the percent change in mass 
was determined from the before and after weights of the samples.  The data were reported 
as percent weight loss ± standard deviation. 
In vitro degradation of the composite CTS-PLGA microspheres was also 
evaluated using KEYENCE VHX 1000 digital microscope to analyze changes in surface 
topography with degradation.  The images of the composite CTS-PLGA microspheres at 
each degradation time point (CP25 and CP50) were compared to the corresponding plain 
CTS microspheres (CP0) for changes in size and surface topography of the microspheres. 
Plain CTS microspheres (CP0) were used as a control for these studies. 
In Vitro Cytocompatibility of Composite CTS-PLGA Microspheres 
The cytocompatibility of the composite CTS-PLGA microspheres was evaluated 
using a human osteosarcoma cell line (Saos-2, ATCC® Number: HTB-85™).   The cell 
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attachment and growth study using Saos-2 cells was conducted in complete growth 
medium composed of McCoy’s 5A Medium + 15% FBS + 1x AB/AM.  Each treatment 
group was gamma sterilized prior to starting the study. 
Briefly, 100 microspheres of each composite CTS-PLGA treatment group were 
placed in glass culture tubes, 13x100mm with screw cap (PYREX
®
 Laboratory 
Glassware, CORNING, MA, USA).  5mL of complete growth medium with cell 
concentration of 10
6
 cells/mL was added to each sample and gently agitated every 15 
mins for four hours to ensure that the microspheres were evenly coated.  After four hours, 
the supernatant from each sample was gently decanted and the number of cells was 
counted using a Z2 Coulter
®
 Particle Count and Size Analyzer (Beckman Coulter, Inc., 
USA) to determine the percentage of cells attached to the surface of each of the 
composite CTS-PLGA microspheres. The data were reported as percent cell attachment ± 
standard deviation. 
To each of the samples, 2mL complete growth medium was added and 
replenished every 48 hours.  Samples were evaluated at days 1, 3, 5 and 7 using the 
CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Wisconsin, USA) to 
determine the growth of cells on the composite CTS-PLGA microspheres based on 
quantification of the ATP present via the luciferase-luciferin reaction.  The data were 
reported as cell number/microsphere ± standard deviation. 
Additionally, at each time point, the samples were evaluated using a 
LIVE⁄DEAD® Viability⁄Cytotoxicity Kit for mammalian cells (Invitrogen Corporation, 
California, USA) to determine the viability of cells on the composite CTS-PLGA 
microspheres based on plasma membrane integrity and esterase activity of the cells.  
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Plain CTS microspheres (CP0) were used as a control for these studies. 
Statistical Analysis 
A two-factor ANOVA with Holm-Sidak post-hoc analysis was used to determine 




 After the formulation of the composite CTS-PLGA microspheres via the 
precipitation method, the actual amount of PLGA within the microspheres was estimated.  
It was found that CP25 actually had 7.5wt% PLGA, while CP50 had 12.7wt% PLGA 
(Table 1).  
 
Table 1. Composite CTS-PLGA formulations and actual CTS and PLGA weight 














CP0 100 0 100 0  
CP25 75 25 92.5 7.5  
CP50 50 50 87.4 12.6  
*
 n=1 
 Confocal image analysis using a Nikon A1 confocal laser microscope system was 
used to validate whether PLGA was incorporated within the composite CTS-PLGA 
microspheres.  Using a 3D stack feature, it appeared that the plain CTS microspheres did 
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not fluoresce in the TRITC range due to the lack of Rhodamine-B encapsulated PLGA 
particles; however, CP0 auto-fluoresced slightly (Image not shown).  For CP50, that had 
PLGA particles encapsulated with Rhodamine-B, the microspheres fluoresced red in the 
TRITC range and all of the fluorescence in CP50 was observed to be well distributed on 
the surface of these composite microspheres (Figure 1A, B and C).  Furthermore, certain 
areas of the composite CTS-PLGA microspheres were not covered by PLGA particles, 
but instead had holes on the surface as indicated in Figure 1C.    
The surface topographical analysis of composite CTS-PLGA microspheres was 
evaluated using a digital microscope. A Quick Depth Composition and 3D feature was 
used on the KEYENCE VHX 1000 digital microscope to get 3D stack images of the 
composite CTS-PLGA microspheres (Figure 2).  Examination of the surface topography 
of the microspheres reveals that as the PLGA content in the CTS microsphere increases, 
there is an increase in a white appearance of the composite CTS-PLGA microspheres as 
compared to CP0.   
 The crystallinity of composite CTS-PLGA microspheres was studied using XRD.  
Representative XRD spectra of the composite CTS-PLGA microspheres, plain CTS 
microspheres and PLGA particles are shown in Figure 3.  CP0 exhibited a large hydrous 
crystalline peak at around 2θ=12
0
 and a very small anhydrous peak at 2θ=20
0
.  With the 
addition of varying amounts of PLGA to the CTS microspheres, the hydrous crystalline 
peak at around 2θ=12
0
 reduced in intensity while the anhydrous peak at 2θ=20
0
 
disappeared.  Hence, both CP25 and CP50 have reduced peaks at 2θ=10
0
 and no 
crystalline peaks at 2θ=20
0
.  Due to the absence of a crystalline peak at 2θ=20
0
, the 
crystallinity indices of composite CTS-PLGA microspheres and plain CTS microspheres 
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could not be calculated.  A small peak, similar to that of CP25, was noticed at around 
2θ=12
0








Figure 1.  Confocal images of composite CTS-PLGA microspheres.  Images were taken 
in the TRITC region with a Nikon A1 confocal laser microscopy using a 10x objective 
and a 3D stack feature.  A: Section of CP50 seen from a default x, y, z view; B: Section 
of CP50 seen from + x-axis; C: Section of CP50 seen from + z-axis.  CP50 fluoresced red 
due to the presence of PLGA within the composite microsphere; all the PLGA particles 
were well distributed on the surface of the microsphere giving it a rough and textured 
surface. Arrow indicates area on the surface of CP50 where holes were observed. 
 
 













CP0 102.3 ± 7.9 300 ± 0.2
*  
CP25 99.9 ± 3.7 298.9 ± 0.3
  
CP50 92.8 ± 0.6 299.2 ± 0.0
  





























Figure 2.  Surface topographical analysis of composite CTS-PLGA microspheres 
compared to plain CTS microspheres. Images were taken using Quick Depth 
Composition and 3D feature on the KEYENCE VHX-1000 digital microscope using a 
100x objective.  CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt% 
PLGA; CP50: CTS microspheres with 50wt% PLGA.  The composite CTS-PLGA 
microspheres (CP25 and CP50) have a visually white surface compared to the plain CTS 
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 The thermal degradation of composite CTS-PLGA microspheres was analyzed 
using DSC.  Representative DSC thermograms and a summary of endothermic and 
exothermic peak temperatures of composite CTS-PLGA microspheres can be found in 
Figure 4 and Table 2 respectively.  DSC analyses revealed that CP0 had a higher 
endothermic peak as compared to CP25 and CP50, however, no differences were seen 
between treatment groups (p = 0.25).  ANOVA analysis showed that there were 
differences in the exothermic peaks between treatment groups (p = 0.0015).  Post-hoc 
analysis revealed that CP0 was different and significantly higher than CP25 and CP50, 








Figure 3.  Representative XRD spectra of composite CTS-PLGA microspheres compared 
with plain CTS microspheres and PLGA particles.  CP0: Plain CTS microspheres; CP25: 
CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt% PLGA.  A 




 is noticed for CP0 with a tiny anhydrous 
peak at 2θ=20
0




 with the 
increase in PLGA content within the composite microspheres. 
Peak @ 2θ =12
0 








































Figure 4.  A. Representative DSC thermograms of composite CTS-PLGA microspheres 





C).  B. Glass transition temperature regions of PLGA particles 
compared with composite CTS-PLGA microspheres.  CP0: Plain CTS microspheres; 
CP25: CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt% 
PLGA.  A slight reduction in exothermic peak temperatures is seen with the incorporation 
of PLGA within the CTS microspheres.   
Exothermic peaks of CTS 
























 The degradation of composite CTS-PLGA microspheres was evaluated over 4 
weeks in a 100μg/mL solution of lysozyme in 1x PBS with 1x AB/AM.  Loss in weight 
of the composite microspheres at each time point was used as a measure of percent 
weight change over time.  Results of two-way ANOVA analysis revealed that there was a 
difference in percent weight change between composite CTS-PLGA treatment groups (p 
< 0.001) as well as a difference between days (p < 0.001) and there was a significant 
interaction between CTS-PLGA treatment groups and day factor (p < 0.001).  Significant 
interaction indicates that the degradation of the composite CTS-PLGA microspheres 
depended upon the composite formulation as well as time spent in the degradation 
solution. The results of the degradation study are summarized in Figure 5. 
 Post-hoc analysis of each composite CTS-PLGA microsphere treatment group 
showed that there was a significant increase in weight loss over the 28 day period with 
the maximum loss seen on day 28.  Furthermore, post-hoc analysis between composite 
CTS-PLGA microspheres on a daily basis showed that there was no difference between 
treatment groups on days 1, 3 and 5.  However, differences were seen on days 7, 14, 21 
and 28, with CP50 and CP0, in general, having the highest and lowest percent weight 
changes respectively.  On day 28, CP50 was significantly different from CP25 and CP0, 
but no differences were seen between CP25 and CP0.  To summarize, at day 28, CP50 
had the largest weight loss of 28.9% ± 1.4%, while CP0 had the lowest weight loss of 
25.2% ± 0.3%. 
  At each time point in the degradation study, images of the composite CTS-PLGA 
microspheres were taken using a digital microscope to evaluate changes in surface 
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topography of the microspheres with degradation time (Figure 6).  It was observed that 
within each treatment group the microspheres reduce in size with degradation time. 
Furthermore, the white appearance of the composite CTS-PLGA microspheres becomes 
less evident with degradation time, becoming more similar to that of plain CTS 
























Figure 5.  Degradation of composite CTS-PLGA microspheres over a 28 day period 
carried out in a 100μg/mL solution of lysozyme in 1x PBS with 1x AB/AM (n=4).  The 
results are represented as percent weight change ± standard deviation on a linear scale.  
CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt% PLGA; CP50: CTS 
microspheres with 50wt% PLGA.  A significant difference in the percent weight change 
was observed between composite CTS-PLGA treatment groups as well as a significant 
difference between days was observed.  At day 28, CP50 had the largest weight loss 
while CP0 had the lowest weight loss. (* difference between groups, p < 0.01; § 
differences vs. all other groups, p < 0.005; † differences against all previous time points, 
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Figure 6.  Digital images of composite CTS-PLGA microspheres over a 28 day 
degradation period carried out in 100μg/mL solution of lysozyme in 1x PBS with 1x 
AB/AM.  CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt% PLGA; 
CP50: CTS microspheres with 50wt% PLGA.  The overall size and white appearance of 
the composite CTS-PLGA microspheres reduce with degradation time when compared to 
plain CTS microspheres.  Scale shown: 500μm 








Cell Attachment and Proliferation Study 
Cellular attachment and proliferation on the composite CTS-PLGA microspheres 
was studied using a human osteosarcoma cell line, Saos-2.  For cellular attachment, one-
way ANOVA analysis revealed that there was a difference in cellular attachment between 
the different composite CTS-PLGA microspheres (p = 0.043).  Post-hoc analysis showed 
that there was a significant difference in the percent cell attachment between CP25 and 
CP0 (p = 0.017); CP25 had the highest percent cell attachment of 35.3% ± 5.5%, while 
CP0 had the lowest percent cell attachment of 23.1% ± 7.7% (Figure 7).   
For proliferation, the results of the two-way ANOVA analysis revealed that there 
was a difference in cellular growth between composite CTS-PLGA treatment groups (p = 
0.006) as well as a difference over time (p < 0.001) and there was a significant interaction 
between CTS-PLGA treatment groups and day factor (p = 0.016).  Significant interaction 
indicates that cellular proliferation on the composite CTS-PLGA microspheres depended 
upon composite formulation and time.  The results of the proliferation study are 
summarized in Figure 8. 
Overall, cells increased in number on all treatment groups over the 7 day cell 
culture period.  At earlier time points, the number of cells/microsphere was higher for 
composite CTS-PLGA treatment groups. However, by day 7, there were no differences 
between the treatment groups.  Post-hoc analysis indicated that there was no significant 
difference in number of cells/microsphere between composite CTS-PLGA microsphere 
groups over the 7 day test period.  On day 1, significant differences in number of 
cells/microsphere were observed between CP0 and composite CTS-PLGA microsphere 
treatment groups.  For each composite CTS-PLGA microsphere treatment group, post-
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hoc analysis showed that there were no significant differences in number of 
cells/microsphere between days for CP25.  For CP0, the number of cells/microsphere on 
day 7 was significantly greater than days 1, 3 and 5.  For CP50, significant increase in the 
number of cells/microsphere was seen between days 3 and 5.   
LIVE/DEAD images of the composite microspheres were taken to assess the 
viability of Saos-2 cells on these microsphere treatment groups at each time point in the 
proliferation study.  Images were taken using a Nikon ECLIPSE TE300 microscope with 
BIOQUANT OSTEO II software (Figure 9).  Qualitatively, it was observed that the 
number of cells/microsphere increases for all treatment groups between days 1 and 3.  
The number of cells/microsphere between days 3, 5 and 7 look similar within each 
treatment group.  Furthermore, no differences in the number of cells/microsphere were 
































Figure 7.  Percent cell attachment of human osteosarcoma epithelial cell line, Saos-2, 
after 4 hours on composite CTS-PLGA microspheres (n=4).  The results are represented 
as percent cell attachment ± standard deviation.  CP0: Plain CTS microspheres; CP25: 
CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt% PLGA.  
CP25 exhibited the highest percent cell attachment, while CP0 exhibited the least percent 
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Figure 8.  Proliferation of human osteosarcoma epithelial cell line, Saos-2, on composite 
CTS-PLGA microspheres over a 7 day period using the CellTiter-Glo® Luminescent 
Cell Viability Assay (n=4).  The results are represented as number of cell/microsphere ± 
standard deviation.  CP0: Plain CTS microspheres; CP25: CTS microspheres with 25wt% 
PLGA; CP50: CTS microspheres with 50wt% PLGA.  Cells increased in number on all 
treatment groups over the 7 day cell culture period.  The number of cells/microsphere 
was higher for composite CTS-PLGA treatment groups at earlier time points, however, 
by day 7, there were no differences seen. (§ differences vs. all other groups, p < 0.05; † 




† p = 0.010 
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Figure 9.  Proliferation of human osteosarcoma epithelial cell line, Saos-2, on composite 
CTS-PLGA microspheres over a 7 day period evaluated using LIVE/DEAD® 
Viability⁄Cytotoxicity Kit for mammalian cells.  CP0: Plain CTS microspheres; CP25: 
CTS microspheres with 25wt% PLGA; CP50: CTS microspheres with 50wt% PLGA.  
The number of cells/microspheres increases between day 1 and 3 for all treatment groups, 
but remains constant thereafter.  At each time point, no differences in number of 
cells/microsphere were observed between treatment groups. 
 








A composite chitosan-poly(lactide-co-glycolide) microsphere based system was 
designed and evaluated for bone tissue engineering applications.  The rationale for this 
design was that acidic degradation by-products of PLGA particles would help to facilitate 
the degradation of CTS microspheres with the ultimate goal of improving the overall 
degradation of composite CTS-PLGA microspheres for bone tissue regeneration.  Our 
primary hypothesis was that the addition of 50:50 PLGA particles to the CTS 
microspheres would increase the overall degradation of the composite microspheres as 
compared to plain CTS microspheres.  Our secondary hypothesis was that the addition of 
50:50 PLGA to the CTS microspheres would have no cytotxic effect on compatibility of 
composite microspheres with osteoblasts.  The effects of varying ratios of PLGA 
particles incorporated into CTS microspheres was examined based on morphology, 
crystallinity, thermal degradation properties, in vitro degradation and in vitro cell 
attachment and proliferation of osteoblasts on composite microspheres as compared to 
plain CTS microspheres. 
We found that the PLGA amount within the various composite CTS-PLGA 
microsphere formulations were lower than the prescribed formulations—only 7.5 wt% 
and 12.6wt% PLGA were incorporated in the CP25 and CP50 formulations respectively 
instead of the theoretical 25wt% and 50wt%.  A 3D stack confocal image of CP50 
revealed that PLGA particles were well distributed on the surface of these microspheres 
and certain areas on the surface had visible holes/voids with no visible PLGA particles.  
These results indicate poor incorporation of PLGA particles within the composite 
microspheres.  The reasons for poor incorporation of PLGA within the composite 
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microspheres may be attributed to a few reasons; 1) degradation of PLGA while in 
chitosan-acetic acid solution prior to precipitation, 2) degradation of PLGA within the 
microspheres prior to neutralization, and 3) degradation and/or loss of PLGA particles 
during washing steps.  In particular, while preparing Rhodamine-B encapsulated PLGA-
CTS microspheres for confocal image analysis, it was observed that the precipitating and 
washing solutions rapidly turned pink indicating loss of Rhodamine-B encapsulated 
PLGA particles during these steps.  Alternative mixing methods, such as using a dual-
syringe system that would mix chitosan in acetic acid solution and PLGA particle 
suspension in water to form microspheres just prior to dripping; and/or other precipitating 
solvents, such as a 0.5M sodium sulfate, 1M sodium hydroxide, and distilled water (3:1:6 
v/v) may be investigated.
81
  Alternatively, other PLGA formulations, such as 85:15 
PLGA, that are not as susceptible to degradation in aqueous solutions may be used and 
investigated.  However, these formulations have slower degradation rates and hence their 
effects on driving the degradation of CTS microspheres may be less pronounced than 
50:50 PLGA.  
Digital microscopy of the microspheres revealed that there was a difference in the 
overall morphology of the composite CTS-PLGA microspheres as compared to plain 
CTS microspheres. Composite microspheres appeared whiter as compared to plain CTS 
microspheres which are a result of the addition of varying contents of PLGA to the CTS 
microspheres. Confocal imaging revealed that the surfaces of composite CTS-PLGA 
microspheres looked rough and textured due to the PLGA particles.  Jiang et al. have 
reported that CTS-PLGA microspheres have a visually rougher surface as compared to 
PLGA microspheres that have a smoother surface.
83
  Findings from confocal imaging 
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show that a majority of the PLGA particles in our composite microspheres is on the 
surface of these microspheres.  The mechanism for why PLGA preferentially segregates 
to the surface is unclear.  It may be due in part because during the preparation of 
composite microspheres the PLGA particles were hydrolyzed either during the mixing, 
precipitation and/or washing processes and hence only residual PLGA material was 
retained on the surface of the composite microsphere.   







However, an absence in crystalline peaks at 2θ=20
0
 was noticed for all treatment groups.  
A similar result was reported by Mecwan et al., wherein CTS sponges prepared by 




  However, Chesnutt et 
al. reported seeing crystalline peaks at 2θ=20
0
 in CTS microspheres that were prepared 
via a similar precipitation method where the microspheres were allowed to precipitate 
and remain in the base solution for 24 hours.
15
  The reason for the loss of the anhydrous 
crystalline peak at 2θ=20
0
 in all the treatment groups may be ascribed to the method used 
to prepare these microspheres as well as differences in DDA of CTS materials used.  
Since the microspheres were only allowed to precipitate and remain in the base solution 
for 5 mins before they were removed and washed, this would not be enough time for the 
crystalline phases within the microspheres to form.  Additionally, it must be noted that 
for this study we used a 61% DDA CTS polymer as compared to a 92.3%DDA CTS 
polymer that was used by Chesnutt et al.
15
  It is well known that CTS polymers with 
higher DDA have higher crystallinity.
89,90
  This is because CTS polymer chains with a 
higher DDA have smaller amino side groups and can pack more efficiently as compared 
to CTS polymer chains with lower DDA which have larger acetyl side groups and cannot 
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pack as efficiently resulting in reduced crystallinity.  Hence, the reduced crystallinity 
seen in all treatment groups is a result of using a CTS polymer with lower DDA.   
Furthermore, as the PLGA content in the composite microspheres was increased, 
a reduction in the hydrous crystalline peak at 2θ=12
0
 was noticed.  50:50 PLGA is an 
amorphous polymer, hence, it would be expected that the increased amount of PLGA in 
the composite CTS-PLGA microspheres would result in the disruption of the crystalline 
chains within CTS polymer, causing the composite CTS-PLGA microspheres to be more 
amorphous as compared to plain CTS microspheres.  These results are similar to Martel-
Estrada et al., wherein they saw a reduction in crystallinity of their chitosan sponges with 
the addition of PLGA.
91
  Interestingly, it was also observed that the composite CTS-PLGA 
microspheres had exothermic peak temperatures that were significantly smaller than that of 
plain CTS microspheres.  However, it must also be noted that the reduction in the 
exothermic peak temperatures seen due to the addition of PLGA to the CTS microspheres 
is very small and may not be practically important.  Furthermore, most chitosan materials 






In vitro degradation studies on composite CTS-PLGA microspheres were 
conducted to evaluate the effect of varying PLGA content in the composite microspheres 
on the degradation of composite microspheres. CP0 had ~15wt% loss after a 14 day 
degradation period as compared to ~2wt% loss reported by Chesnutt et al. for the same 
degradation time.
15
  This discrepancy in the degradation of plain chitosan microspheres 
can be attributed to the reduced crystallinity of CP0 which would have resulted in higher 
degradation due to loser chain packing of the CTS polymer making the polymer chains 
more susceptible to enzymatic degradation by lysozyme as compared to the highly 
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crystalline chitosan microspheres (crystallinity index of ~80%) prepared by Chesnutt et 
al.
15
  It was hypothesized that the addition of 50:50 PLGA particles to the CTS 
microspheres would increase their overall degradation rate as the acidic degradation by-
products of PLGA would help CTS microspheres to degrade faster.  Jiang et al. reported 
that the addition of CTS to PLGA microspheres reduced the degradation rate of their 
composite CTS-PLGA sintered microspheres to ~0.5wt% loss as compared to 1.5wt% 
loss seen for PLGA sintered scaffolds after 12 weeks of degradation.
84
  Hence, the results 
of our degradation study correlates with that of Jiang and coworkers—as the weight 
percent of CTS in the composite microspheres increase their degradation rates are lower 
as compared to composite microspheres with higher weight percent of PLGA.   
Furthermore, from the digital images of the composite CTS-PLGA microspheres 
taken during the degradation study it can be seen that the microsphere size of all 
treatment groups reduce over time which would suggest overall degradation of the 
microspheres. Moreover, the whiter appearance of the composite CTS-PLGA 
microspheres also reduces over time, and by day 28, all treatment groups look similar to 
each other.  This difference in appearance of the composite CTS-PLGA microspheres, as 
previously stated, is attributed to the addition of PLGA to the CTS microspheres.  Hence, 
a reduction in the whiter appearance of composite microspheres over time would suggest 
that the PLGA portion of the composite microspheres is degrading at a rate faster than the 
CTS portion of the microspheres.  This result is not surprising as we used 50:50 PLGA in 
our composite microspheres which is known to degrade within 1-2 months.
74
  At this 
point, however, it is uncertain whether any loss in mass seen in the composite 
microspheres was solely due to PLGA particles or a combinatory effect of PLGA 
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particles and a lower crystalline CTS polymer.  Furthermore, the mechanism by which 
PLGA aids in the degradation of CTS is presently unknown and further studies would 
need to be conducted to understand this mechanism.  This would be important so that the 
degradation rate of the CTS microspheres can be optimized and tailored for specific bone 
tissue engineering applications by the addition of varying amounts of PLGA. 
In vitro cell viability studies on composite CTS-PLGA microspheres were 
conducted to observe if there were any cytotoxic effects associated with the varying 
amounts of PLGA within the composite microspheres due to its acidic degradation 
products.  CP0 had a cell attachment of ~23% Saos-2 cell attachment as compared to the 
observed 42% and 55% HEPM cell attachments reported by Reves et al. and Chesnutt et 
al. respectively for composite chitosan-hydroxyapatite microsphere scaffolds.
15,17
  This 
reduced attachment seen for CP0 and the other treatment groups can be a result of a 
higher seeding density used for this study (5 x 10
6
 cells/sample) as compared to the 10
5
 
cells/sample seeding concentrations used by Reves et al and Chesnutt et al.
15,17
  
Additionally, some cells may have attached to the glass culture tubes which were not 
accounted for; as a result, we may have underestimated the percent cell attachment.  
Furthermore, it is widely known that surface topography and roughness of materials plays 
an important role in cellular attachment and proliferation.
93,94
  From the in vitro cell 
attachment studies it was observed that the presence of PLGA within the composite CTS-
PLGA microspheres significantly impacted the attachment of Saos-2 cells on the 
microspheres.  As noted earlier, the composite CTS-PLGA microspheres exhibited a 
more roughened texture than plain CTS microspheres which may have resulted in a 
greater percent cell attachment for the composite CTS-PLGA microspheres.  
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Furthermore, it was also observed that CP25 showed a greater, but not significant, 
percent cell attachment than CP50.  It is known that PLGA is a hydrophobic polymer and 
hence, increasing the PLGA content of the composite microspheres would increase the 
overall hydrophobicity of the surface of the composite microsphere and prevent cell 
attachment proteins to bind to such surfaces.
95,96
  Hence, the differences in the attachment 
of Saos-2 cells to the composite CTS-PLGA can be attributed to a combination of the 
differences in the surface topography and hydrophobicity of the composite CTS-PLGA 
microspheres.   
Moreover, the in vitro proliferation study as well as LIVE/DEAD images of the 
microspheres revealed that there were no differences in number of cells/microsphere 
between the treatment groups over the 7 day period.  However, it should be noted that the 
cells on CP0 grew at a faster rate, but not significantly, when compared to composite 
CTS-PLGA microspheres.  It is well known that PLGA materials produce acidic 
degradation by-products which inhibit cellular growth.  This may be the case with our 
composite CTS-PLGA microspheres too, but the added benefit of a more favorable 
surface for the cells to attach and proliferate on the composite CTS-PLGA microspheres 
could potentially counteract the deleterious effects the acidic degradative by-products of 
PLGA may have on osteoblastic cellular growth.  Overall, these findings are in 
accordance with the results by Nandagiri et al., who reported that the addition of PLGA 
nanoparticles to chitosan-gelatin scaffolds did not significantly affect cell attachment and 
viability of clonal human osteoblast cell line, hFOB, over an 11 day cell culture period.
82
  
Hence, we can support our hypothesis that incorporating 50:50 PLGA into CTS 
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microspheres will have no cytotoxic effect on compatibility of composite CTS-PLGA 
microspheres with osteoblasts.   
The results of this study show that even though all PLGA particles did not get 
incorporated into the composite CTS-PLGA microspheres, there are PLGA particles on 
the surface.  This layer of PLGA particles on the surface could act as a barrier to slow 
down release of drugs that are encapsulated within the CTS microsphere, and to test the 
potential of these composite CTS-PLGA microspheres as potential drug delivery 
vehicles, future studies will be aimed at loading the PLGA particles and CTS 
microspheres with drugs and assessing the dual drug release kinetics from these 
composite microspheres. Furthermore, it would be of interest, primarily from a tissue 
engineering and drug delivery point of view, to fabricate these composite CTS-PLGA 
microspheres into 3D bone constructs and assess these constructs to regenerate bone in an 
in vivo model.  
Conclusions 
A new composite CTS-PLGA microsphere based system was successfully 
fabricated via a precipitation method. The precipitation method used to prepare the 
composite CTS-PLGA microspheres resulted in only a small amount of PLGA being 
incorporated into the composite microspheres as compared to the theoretical formulations 
of the composite microspheres.  Moreover, the PLGA within the composite microspheres, 
being hydrophobic, preferentially segregated to the surface of the microsphere, resulting 
in a roughened texture of the composite CTS-PLGA microspheres.  Furthermore, the 
addition of PLGA to the CTS microspheres resulted in a reduced crystallinity which can 
be reflected in the reduced exothermic peak temperatures; had higher weight loss at the 
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end of 28 days as well as exhibited better cellular attachment.  However, there were no 
differences seen in the proliferation of osteoblasts between the plain CTS microspheres 
and composite CTS-PLGA microspheres at the end of the 7 day cell culture period.  
Overall, even though only a small portion of PLGA was incorporated into the composite 
microsphere, they had higher degradation and better cell attachment properties compared 
to plain CTS microspheres, showing that these composite CTS-PLGA microspheres have 
a good potential as bone graft substitutes in bone tissue engineering applications.     
Acknowledgements 
We would like to acknowledge Dr. Sanjay Mishra for his help with obtaining 
XRD data of the composite CTS-PLGA microspheres.  Furthermore, we would like to 
thank Dr. Omar Skalli and Ms. Lou Boykins from the Integrated Microscopy Center at 
the University of Memphis, with their help in obtaining confocal images of the composite 
CTS-PLGA microspheres.  This work was conducted in the Biomaterials Applications of 
Memphis (BAM) laboratories at the University of Memphis, Memphis, TN. 
References 
1. Chapter 6: Musculoskeletal Injuries. The Burden of Musculoskeletal Disease in the 
United States: American Academy of Orthopaedic Surgeons; 2008. p 123-162. 
2. Chesnutt BM, Yuan Y, Brahmandam N, Yang Y, Ong JL, Haggard WO, Bumgardner JD. 
Characterization of biomimetic calcium phosphate on phosphorylated chitosan films. 
Journal of Biomedical Materials Research Part A 2007;82A(2):343-353. 
3. Glassman SD, Carreon LY, Campbell MJ, Johnson JR, Puno RM, Djurasovic M, Dimar 
JR. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion. 
Spine Journal 2008;8(3):443-8. 
52 
 
4. Khan SN, Cammisa FP, Jr., Sandhu HS, Diwan AD, Girardi FP, Lane JM. The biology of 
bone grafting. Journal of the American Academy of Orthopaedic Surgeons 
2005;13(1):77-86. 
5. Khan Y, Yaszemski MJ, Mikos AG, Laurencin CT. Tissue engineering of bone: material 
and matrix considerations. Journal of Bone and Joint Surgery-American Volume 2008;90 
Suppl 1:36-42. 
6. Nandi SK, Roy S, Mukherjee P, Kundu B, De DK, Basu D. Orthopaedic applications of 
bone graft & graft substitutes: a review. Indian Journal of Medical Research 
2010;132:15-30. 
7. Dahabreh Z, Dimitriou R, Giannoudis PV. Health economics: a cost analysis of treatment 
of persistent fracture non-unions using bone morphogenetic protein-7. Injury 
2007;38(3):371-7. 
8. Moore WR, Graves SE, Bain GI. Synthetic bone graft substitutes. ANZ Journal of 
Surgery 2001;71(6):354-61. 
9. Burchardt H. The biology of bone graft repair. Clin Orthop Relat Res 1983(174):28-42. 
10. Parikh SN. Bone graft substitutes: past, present, future. Journal of Postgraduate Medicine 
2002;48(2):142-8. 
11. Bumgardner JD, Wiser R, Gerard PD, Bergin P, Chestnutt B, Marini M, Ramsey V, Elder 
SH, Gilbert JA. Chitosan: potential use as a bioactive coating for orthopaedic and 
craniofacial/dental implants. Journal of Biomaterials Science-Polymer Edition 
2003;14(5):423-438. 
12. Di Martino A, Sittinger M, Risbud MV. Chitosan: a versatile biopolymer for orthopaedic 
tissue-engineering. Biomaterials 2005;26(30):5983-90. 
13. Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials 
2003;24(13):2339-49. 
14. Kim IY, Seo SJ, Moon HS, Yoo MK, Park IY, Kim BC, Cho CS. Chitosan and its 
derivatives for tissue engineering applications. Biotechnology Advances 2008;26(1):1-
21. 




16. Shi CM, Zhu Y, Ran XZ, Wang M, Su YP, Cheng TM. Therapeutic potential of chitosan 
and its derivatives in regenerative medicine. Journal of Surgical Research 
2006;133(2):185-192. 
17. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, Dhawan S. 
Chitosan microspheres as a potential carrier for drugs. International Journal of 
Pharmaceutics 2004;274(1-2):1-33. 
18. Bhat A, Dreifke MB, Kandimalla Y, Gomez C, Ebraheim NA, Jayasuriya AC. Evaluation 
of cross-linked chitosan microparticles for bone regeneration. Journal of Tissue 
Engineering and Regenerative Medicine 2010;4(7):532-42. 
19. Stephan SJ, Tholpady SS, Gross B, Petrie-Aronin CE, Botchway EA, Nair LS, Ogle RC, 
Park SS. Injectable tissue-engineered bone repair of a rat calvarial defect. Laryngoscope 
2010;120(5):895-901. 
20. Chesnutt BM, Viano AM, Yuan YL, Yang YZ, Guda T, Appleford MR, Ong JL, 
Haggard WO, Burngardner JD. Design and characterization of a novel 
chitosan/nanocrystalline calcium phosphate composite scaffold for bone regeneration. 
Journal of Biomedical Materials Research Part A 2009;88A(2):491-502. 
21. Chesnutt BM, Yuan YL, Buddington K, Haggard WO, Bumgardner JD. Composite 
Chitosan/Nano-Hydroxyapatite Scaffolds Induce Osteocalcin Production by Osteoblasts 
In Vitro and Support Bone Formation In Vivo. Tissue Engineering Part A 
2009;15(9):2571-2579. 
22. Reves BT, Jennings JA, Bumgardner JD, Haggard WO. Osteoinductivity Assessment of 
BMP-2 Loaded Composite Chitosan-Nano-Hydroxyapatite Scaffolds in a Rat Muscle 
Pouch. Materials 2011;4(8):1360-1374. 
23. Cohen S, Alonso MJ, Langer R. Novel approaches to controlled-release antigen delivery. 
International Journal of Technology Assessment in Health Care 1994;10(1):121-30. 
24. Jalil R, Nixon JR. Biodegradable Poly(Lactic Acid) and Poly(Lactide-Co-Glycolide) 
Microcapsules - Problems Associated with Preparative Techniques and Release 
Properties. Journal of Microencapsulation 1990;7(3):297-325. 
25. Kitchell JP, Wise DL. Poly(Lactic Glycolic Acid) Biodegradable Drug Polymer Matrix 
Systems. Methods in Enzymology 1985;112:436-448. 




27. Yilgor P, Tuzlakoglu K, Reis RL, Hasirci N, Hasirci V. Incorporation of a sequential 
BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering. 
Biomaterials 2009;30(21):3551-9. 
28. Jiang T, Abdel-Fattah WI, Laurencin CT. In vitro evaluation of chitosan/poly(lactic acid-
glycolic acid) sintered microsphere scaffolds for bone tissue engineering. Biomaterials 
2006;27(28):4894-4903. 
29. Yuan Y, Chesnutt BM, Utturkar G, Haggard WO, Yang Y, Ong JL, Bumgardner JD. The 
effect of cross-linking of chitosan microspheres with genipin on protein release. 
Carbohydrate Polymers 2007;68(3):561-567. 
30. Mecwan MM, Rapalo GE, Mishra SR, Haggard WO, Bumgardner JD. Effect of 
molecular weight of chitosan degraded by microwave irradiation on lyophilized scaffold 
for bone tissue engineering applications. Journal of Biomedical Materials Research Part 
A 2011;97A(1):66-73. 
31. Trung TS, Thein-Han WW, Qui NT, Ng CH, Stevens WF. Functional characteristics of 
shrimp chitosan and its membranes as affected by the degree of deacetylation. 
Bioresource Technology 2006;97(4):659-63. 
32. Baskar D, Kumar T. Effect of deacetylation time on the preparation, properties and 
sweeling behavior of chitosan films. Carbohydrate Polymers 2009;78(4):767-772. 
33. Martel-Estrada SA, Martinez-Perez CA, Chacon-Nava JG, Garcia-Casillas PE, Olivas-
Armendariz I. Synthesis and thermo-physical properties of chitosan/poly(DL-lactide-co-
glycolide) composites prepared by thermally induced phase separation. Carbohydrate 
Polymers 2010;81(4):775-783. 
34. Yuan Y, Chesnutt BM, Haggard WO, Bumgardner JD. Deacetylation of Chitosan: 
Material Characterization and in vitro Evaluation via Albumin Adsorption and Pre-
Osteoblastic Cell Cultures. Materials 2011;4(8):1399-1416. 
35. Jiang T, Nukavarapu SP, Deng M, Jabbarzadeh E, Kofron MD, Doty SB, Abdel-Fattah 
WI, Laurencin CT. Chitosan-poly(lactide-co-glycolide) microsphere-based scaffolds for 
bone tissue engineering: In vitro degradation and in vivo bone regeneration studies. Acta 
Biomaterialia 2010;6(9):3457-3470. 
36. Reves BT, Bumgardner JD, Cole JA, Yang Y, Haggard WO. Lyophilization to improve 
drug delivery for chitosan-calcium phosphate bone scaffold construct: a preliminary 




37. Borsari V, Giavaresi G, Fini M, Torricelli P, Salito A, Chiesa R, Chiusoli L, Volpert A, 
Rimondini L, Giardino R. Physical characterization of different-roughness titanium 
surfaces, with and without hydroxyapatite coating, and their effect on human osteoblast-
like cells. Journal of Biomedical Materials Research Part B Applied Biomaterials 
2005;75(2):359-68. 
38. Mustafa K, Wennerberg A, Wroblewski J, Hultenby K, Lopez BS, Arvidson K. 
Determining optimal surface roughness of TiO(2) blasted titanium implant material for 
attachment, proliferation and differentiation of cells derived from human mandibular 
alveolar bone. Clinical Oral Implants Research 2001;12(5):515-25. 
39. Weiss L, Blumenson LE. Dynamic adhesion and separation of cells in vitro. II. 
Interactions of cells with hydrophilic and hydrophobic surfaces. Journal of Cellular 
Physiology 1967;70(1):23-32. 
40. Bacakova L, Filova E, Parizek M, Ruml T, Svorcik V. Modulation of cell adhesion, 
proliferation and differentiation on materials designed for body implants. Biotechnology 
Advances 2011;29(6):739-67. 
41. Nandagiri VK, Gentile P, Chiono V, Tonda-Turo C, Matsiko A, Ramtoola Z, 
Montevecchi FM, Ciardelli G. Incorporation of PLGA nanoparticles into porous 
chitosan-gelatin scaffolds: influence on the physical properties and cell behavior. Journal 





CHAPTER 4: CONCLUSIONS 
 In this preliminary in vitro study, novel composite CTS-PLGA microspheres for 
bone tissue engineering applications were successfully fabricated using a precipitation 
method.  The potential of these composite CTS-PLGA microspheres in bone tissue 
engineering applications was assessed by evaluating the physiochemical, degradative and 
biological effects of incorporating varying amounts of PLGA particles into CTS 
microspheres.   
It was found that the precipitation method used to prepare the composite CTS-
PLGA microspheres resulted in only a small amount of PLGA being incorporated into 
the composite microspheres as compared to the theoretical formulations of the composite 
microspheres.  Moreover, the PLGA within the composite microspheres, being 
hydrophobic, preferentially segregated to the surface of the microsphere as compared to 
the aqueous core of the microspheres.  This resulted in a roughened texture of the 
composite CTS-PLGA microspheres as compared to plain CTS microspheres.  
Furthermore, the addition of PLGA to the CTS microspheres resulted in a reduced 
crystallinity of the composite microspheres which can be reflected in the reduced 
exothermic peak temperatures of the composite CTS-PLGA microspheres as compared to 
the plain CTS microspheres. 
Overall, even though the incorporation of PLGA was low within the composite 
CTS-PLGA microspheres, they had a higher weight loss or degradation at the end of 28 
days as well as better cellular attachment as compared to plain CTS microspheres.  
However, there were no differences seen in the proliferation of osteoblasts between the 
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plain CTS microspheres and composite CTS-PLGA microspheres at the end of the 7 day 
cell culture period.  
Hence, the results of our study show that we can support our hypotheses that the 
incorporation of PLGA into CTS microspheres increased the overall degradation rate of 
the microspheres; and the composite CTS-PLGA microspheres were compatible with 
osteoblasts and had no evident deleterious effects due to the acidic degradation by-




CHAPTER 5: FUTURE WORK 
The results of this study showed that only a small amount of PLGA was actually 
incorporated into the microspheres as compared to the theoretical formulations of the 
composite microspheres. This reduced amount was attributed to the extremely alkaline 
base solution that was used to precipitate the composite microspheres which may have 
resulted in preliminary degradation of the PLGA particles.  Hence, future studies will aim 
at exploring alternative base solutions and methods for the precipitation of these 
composite microspheres as well as methods for a more uniform distribution of PLGA 
particles within the microspheres; to allow for maximum incorporation of PLGA within 
the composite microspheres. This will result in maximum loading and minimal loss of a 
drug of interest within PLGA particles and will be particularly important from a drug 
delivery perspective.  
Furthermore, the results of this study suggest that the composite CTS-PLGA 
microsphere based system may have the potential to be used as a dual drug delivery 
vehicle for bone tissue engineering applications.  A possible suggestion is to encapsulate 
a hydrophobic drug within the PLGA particles while hydrophilic drugs can be 
encapsulated within the CTS microsphere.  The PLGA particles that segregated to the 
surface of the composite microsphere would provide a means for rapid delivery of the 
hydrophobic drug, whereas, the hydrophilic drug encapsulated within the CTS 
microspheres would have an extended release as the PLGA particles on the surface of the 
microsphere would act as a barrier, slowing down the release of the drug from the 
microsphere.  To test these composite CTS-PLGA microspheres as potential dual drug 
delivery vehicles, future studies will be aimed at loading the PLGA particles and CTS 
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microspheres with hydrophobic and hydrophilic drugs respectively, as mentioned above, 
and assessing the dual drug release kinetics from these composite microspheres. 
Moreover, different methods and techniques for fusing these composite CTS-
PLGA microspheres to fabricate them into 3D bone scaffold constructs and studying their 
mechanical properties should be explored.  Moreover, it would be of interest to conduct a 
long-term degradation study on these composite CTS-PLGA bone scaffold constructs and 
evaluate their mechanical integrity over the degradation time period.  It may also be 
important to evaluate the long term effects of cell growth pattern on the composite CTS-
PLGA bone scaffold constructs as well as the evaluation of other cellular parameters and 
bone cell mineralization markers, such as alkaline phosphatase, calcium content, collagen 
type I, collagen type II, osteopontin, osteocalcin and bone sialoprotein.   
Finally, it would be of interest, primarily from a bone tissue engineering and drug 
delivery point of view, to assess the ability of these composite CTS-PLGA 3D 
microsphere based scaffolds to form new bone tissue, while simultaneously degrading and 
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APPENDIX A: PREPARATION OF CP5 COMPOSITE MICROSPHERES 
CP5 composite microspheres or 5 wt% PLGA particles within chitosan 
microspheres were prepared similarly to the other composite CTS-PLGA weight 
formulations as previously described.  Briefly, a 4.375 wt% solution of CTS powder 
(Degree of deacetylation—61%, Viscosity—124cP, Primex, Iceland) was prepared in 2.5 
v/v% acetic acid solution and allowed to dissolve for 48 hours and then filtered using a 
nylon mesh with a pore diameter of 180μm (Gilson Company, Inc., Ohio, USA).  PLGA 
particles suspended in water were added to the filtered CTS solution so that the final 
concentration of PLGA in the solution was 5wt%.  To form microspheres, the PLGA-
CTS solutions were dripped using a 16G needle and a syringe pump set at a flow rate of 
10μL/min into a cold base solution (50 wt% DI water, 30 wt% methanol, and 20 wt% 
sodium hydroxide) to precipitate microspheres.  The microspheres were allowed to sit in 
the base solution for 5 mins before being collected.  Each batch of collected CP5 
composite microspheres was then washed thoroughly with DI water to neutral pH and 
tested using a pH paper.  The CTS-PLGA microspheres were air dried in a fume hood 
overnight. 
Once prepared, physiochemical characterization, in vitro degradation studies and 
in vitro cellular attachment and proliferation studies were performed on CP5 composite 
microspheres as described in the subsequent appendices.  
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APPENDIX B: PHYSIOCHEMICAL CHARACTERIZATION OF CP5 
COMPOSITE MICROSPHERES 
The physicochemical characterization of CP5 composite microspheres was 
evaluated using XRD spectrometry to evaluate changes in crystallinity; and DSC to 
evaluate thermal degradation properties. 
As previously described, XRD analysis on CP5 microspheres was performed on a 
Bruker D8 Advance (Bruker AXS Inc., Madison, WI) using Cu-Kα radiation at 40 kV and 
40mA.  The diffraction patterns were obtained in the 2θ scan range of 4-40
0
 with a step 
size of 0.05
0
 and a time/step of 0.2 s.  DSC analysis of composite CTS-PLGA 
microspheres was performed on a NETZSCH DSC 200 PC (NETZSCH DSC 






C/min.  The 
XRD and DSC scans (n=3) for CP5 composite microspheres were compared to the scans 
of plain CTS microspheres (CP0) and PLGA particles.  
The results of XRD analysis revealed that CP5 had crystalline peaks at 2θ = 12
0
 
and 2θ = 20
0
 as compared to CP0 which had a large hydrous crystalline peak at 2θ = 12
0
 
but an almost absent anhydrous crystalline peak at 2θ = 20
0
 (Figure 1).  However, with 
the increase in PLGA content it is noticed that the hydrous crystalline peak at 2θ = 12
0
 
reduces (Figure 1).     
The results of DSC analysis revealed that there were no differences in the 
endothermic peak temperatures between CP0 and CP5 (p = 0.963).  However, CP5 had a 
significantly lower exothermic temperature of 298.6 ± 0.1
0
C as compared to CP0 with 
exothermic temperatures of 300.0 ± 0.2
0
C (p < 0.001).  This reduction in exothermic 
temperature may be attributed to the addition of PLGA.  It must be noted that the 
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Figure 1.  Representative XRD spectra of CP5, CTS microspheres with 5wt% PLGA, 





 is noticed for CP0 with a tiny anhydrous peak at 2θ=20
0
. A 
decrease in peak size is seen at around 2θ=12
0
, but a crystalline anhydrous peak at 2θ=20
0
 
is seen for CP5.   
Figure 2.  Representative DSC spectra of CP5, CTS microspheres with 5wt% PLGA, 
compared with plain CTS microspheres (CP0) and PLGA particles. A reduction in 
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APPENDIX C: IN VITRO DEGRADATION OF CP5 COMPOSITE 
MICROSPHERES 
The in vitro degradation of CP5 composite microspheres was also evaluated over 
a 4 week period: Days 1, 3, 5, 7, 14, 21 and 28.  A degradation solution of 100μg/mL 
concentration of lysozyme in 1x PBS with 1x AB/AM (Penicillin-10,000 IU/mL, 
Streptomycin-10mg/mL, Amphotericin B-25µg/mL) was used.  Each treatment group 
was gamma sterilized prior to starting the study.   
As previously described, CP5 samples (n=4) were weighed and placed in glass 
scintillation vials.  To each sample, 2mL of degradation solution was added and the 
samples were placed in an incubator at 37
0
C with constant shaking using a plate rocker.  
Every 72 hours, for 4 weeks, degradation solutions were replenished.  At each time point, 
the samples were washed with DI water three times before drying in an oven at 40
0
C for 
24 hours, weighed and the percent change in mass was determined from the before and 
after weights of the samples.  The data were reported as percent weight loss ± standard 
deviation.  In vitro degradation of CP5 composite microspheres were also evaluated using 
KEYENCE VHX 1000 digital microscope to analyze changes in surface topography with 
degradation.   
The results of the one-way ANOVA analysis showed that there was an increase in 
weight percent loss of CP5 microspheres over the 28 day degradation period (p < 0.001).  
Post-hoc analysis revealed that there were no differences between days 1, 3, 5 and 7.  
However, differences were noticed between days 14, 21 and 28. Overall, at the end of the 
28 day degradation period, CP5 had a weight percent loss of 26.2 % ± 0.9% (Figure 3).  






Day 0 Day 7 Day 14 Day 21 Day 28 
Figure 4.  Digital images of CP5, CTS microspheres with 5wt% PLGA, over a 28 day 
degradation period carried out in 100μg/mL solution of lysozyme in 1x PBS with 1x 
AB/AM.  The overall size and white, glass-like texture of the composite CTS-PLGA 
microspheres reduce with degradation time similar to the other composite CTS-PLGA 
microspheres. Scale shown: 500μm 
as the white texture of the microspheres reduces over the 28 day degradation time period 






Figure 3.  Degradation of CP5, CTS microspheres with 5wt% PLGA, over a 28 day 
period carried out in a 100μg/mL solution of lysozyme in 1x PBS with 1x AB/AM 
(n=4).  The results are represented as percent weight change ± standard deviation.  At 
day 28, CP5 had a weight loss of 26.2% ± 0.9%. († differences against all previous time 
points, p < 0.001) 
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APPENDIX D: IN VITRO CELL ATTACHMENT AND PROLIFERATION ON 
CP5 COMPOSITE MICROSPHERES 
The cytocompatibility of CP5 composite microspheres was evaluated using a 
human osteosarcoma cell line (Saos-2, ATCC® Number: HTB-85™).   The cell 
attachment and growth study using Saos-2 cells was conducted in complete growth 
medium composed of McCoy’s 5A Medium + 15% FBS + 1x AB/AM.  Each treatment 
group was gamma sterilized prior to starting the study. 
As previously describe, 100 microspheres of CP5 were placed in glass culture 
tubes, 13x100mm with screw cap (PYREX
®
 Laboratory Glassware, CORNING, MA, 
USA).  5mL of complete growth medium with cell concentration of 10
6
 cells/mL was 
added to each sample and gently agitated every 15 mins for four hours to ensure that the 
microspheres were evenly coated.  After four hours, the supernatant from each sample 
was gently decanted and the number of cells was counted using a Z2 Coulter
®
 Particle 
Count and Size Analyzer (Beckman Coulter, Inc., USA) to determine the percentage of 
cells attached to the surface of CP5 composite microspheres. The data were reported as 
percent cell attachment ± standard deviation. 
To CP5 samples, 2mL complete growth medium was added and replenished every 
48 hours.  Samples were evaluated at days 1, 3, 5 and 7 using the CellTiter-Glo® 
Luminescent Cell Viability Assay (Promega, Wisconsin, USA) to determine the growth 
of cells on CP5 based on quantification of the ATP present via the luciferase-luciferin 
reaction.  The data were reported as cell number/microsphere ± standard deviation.  
Additionally, at each time point, CP5 samples were evaluated using a LIVE⁄DEAD® 
Viability⁄Cytotoxicity Kit for mammalian cells (Invitrogen Corporation, California, USA) 
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to determine the viability of cells based on plasma membrane integrity and esterase 
activity of the cells.  
For cellular attachment, one-way ANOVA analysis revealed that there was a 
difference in cellular attachment between the different composite CTS-PLGA 
microspheres (p = 0.035).  However, post-hoc analysis showed that there were no 
significant differences between CP0 and CP5; CP5 had a 32.7% ± 3.4% cell attachment 
as compared to 23.1% ± 7.7% cell attachment seen for CP0 (Table 1). 
 
Table 1. Percent Saos-2 cell attachment on CP5 compared with other composite 
Chitosan-PLGA microspheres and plain CTS microspheres 
Composite  
CTS-PLGA formulation 
Cell attachment  
(%) 
 
CP5 32.7 ± 3.4 
 
CP0 23.1 ± 7.7 
 
CP25 35.3 ± 5.5 
 
CP50 30.2 ± 4.3 
 
 
For proliferation, the results of the one-way ANOVA analysis revealed that there 
were no differences in cellular growth on CP5 over time (p = 0.089) (Figure 5).  
LIVE/DEAD images of CP5 composite microspheres were taken using a Nikon 
ECLIPSE TE300 microscope with BIOQUANT OSTEO II software (Figure 6). 
Qualitatively, it was observed that the number of cells/microsphere increases between 
days 3 and 5.  However, no difference in the number of cells/microsphere is seen between 
days 1 and 3, and days 5 and 7. 
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Figure 5.  Proliferation of human osteosarcoma epithelial cell line, Saos-2, on CP5, 
CTS microspheres with 5wt% PLGA, over a 7 day period evaluated using the 
CellTiter-Glo® Luminescent Cell Viability Assay (n=4).  No significant differences 
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Figure 6.  Proliferation of human osteosarcoma epithelial cell line, Saos-2, on CP5, 
CTS microspheres with 5wt% PLGA, over a 7 day period evaluated using 
LIVE/DEAD® Viability⁄Cytotoxicity Kit for mammalian cells.  The number of 
cells/microsphere appears to increase between days 3 and 5 and remains constant 
between days 1 and 3, and days 5 and 7. 
